News

  1. ActiGraph Launches ActiLife Mobile App 1/14/2013

    ActiGraph, a leading provider of objective patient monitoring solutions for the global research community, recently announced the release of a new mobile app for researchers.

  2. Tranzyme Pharma Announces Top-Line Results Of TZP-102 Phase 2b Trial 11/15/2012

    Tranzyme Pharma (Nasdaq:TZYM), today announced top-line results of the preliminary analysis of the first of two Phase 2b trials assessing the safety and efficacy of its oral ghrelin agonist, TZP-102 in diabetic patients with gastroparesis.

  3. Zafgen Announces Initiation Of Phase 2a Clinical Development With Beloranib In Obesity 11/6/2012

    Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced that it has initiated Phase 2a clinical testing of  beloranib.

  4. Janssen Announces Collaboration With Vertex On Phase 2 Study To Investigate An All-Oral Regimen Of Simeprevir (TMC435) And VX-135 For Treatment Of Hepatitis C 11/1/2012

    Janssen Pharmaceuticals, Inc. today announced that it has entered into a non-exclusive collaboration with Vertex Pharmaceuticals Incorporated to evaluate in a Phase 2 study the safety and efficacy of an all-oral regimen for the treatment of hepatitis C (HCV).

  5. Novartis To Start Construction Of New Biotechnology Facility In Singapore With An Investment Of Over USD 500 Million 10/31/2012

    ​Novartis announced recently the construction of a new state-of-the-art biotechnology production site in Singapore with an investment valued at over USD 500 million. The new facility will focus on drug substance manufacturing based on cell culture technology.

  6. ViaCyte Receives $10.1M Strategic Partnership Award From CIRM To Continue Development Of Diabetes Therapy 10/26/2012

    ViaCyte, Inc., a leading regenerative medicine company developing a transformative cell therapy for treatment of diabetes, announced today that it has received a $10.1 million Strategic Partnership Award from the California Institute for Regenerative Medicine (CIRM).

  7. Lilly Diabetes Announces Positive Results Of Phase III Trials Of Dulaglutide In Type 2 Diabetes 10/22/2012

    Eli Lilly and Company (NYSE: LLY) today announced positive top-line results of three completed Phase III AWARD trials for dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) analog being studied as a once-weekly treatment for type 2 diabetes.

  8. Second Phase 2 Trial Of Telotristat Etiprate Shows Positive Results In Carcinoid Syndrome 10/12/2012

    Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced positive, top-line data from a recently completed Phase 2 study in carcinoid syndrome with telotristat etiprate.

  9. First Results From Phase 3 CANVAS Trial Show Canagliflozin As Add-on Therapy To Insulin Lowered Blood Sugar Levels In Patients With Type 2 Diabetes At An Elevated Risk For Cardiovascular Disease 10/2/2012

    Janssen Research & Development, LLC (Janssen) today announced that use of the investigational medicine canagliflozin substantially lowered blood glucose levels when used as add-on therapy in patients on insulin therapy for type 2 diabetes and who are considered to be at greater risk for cardiovascular disease.

  10. Kinexum And Pennington Biomedical Announce Collaboration For Accelerating Clinical Research Innovation 9/24/2012

    Kinexum and Pennington Biomedical Research Center announced plans to establish an integrated approach for emerging companies and early stage therapies to achieve high value regulatory and early phase human clinical trials.